Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03050164
Recruitment Status : Completed
First Posted : February 10, 2017
Last Update Posted : February 10, 2017
Sponsor:
Information provided by (Responsible Party):
Hunan Kelun Pharmaceutical Co., Ltd.

Brief Summary:
The study design is an Open-Label,Randomized, Single-Dose, 2-way Crossover Bioequivalence Study. During each session, the subjects will be administered a single dose of 250mg Gefitinib Tablet (one Gefitinib Tablet 250mg of Hunan Kelun or one Iressa® Tablet 250mg of AstraZeneca) under fasting conditions.

Condition or disease Intervention/treatment Phase
Bioequivalence Study Drug: Gefitinib Tablet 250mg of Hunan Kelun Drug: Iressa® Tablet 250mg of AZN Phase 1

Detailed Description:
An Open-Label,Randomized, Single-Dose, 2-way Crossover Bioequivalence Study. During each session, the subjects were randomly assigned in a 1:1 ratio to receive a single 250-mg dose of either the test formulation(Hunam Kelun) or the reference formulation(Iressa® Astrazeneca), and vice versa, with a 21-day washout period between administration periods.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 38 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Other
Official Title: Single-dose, Open-label, Randomized, 2-way Crossover Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions in Chinese Healthy Male Subjects
Actual Study Start Date : September 8, 2016
Actual Primary Completion Date : November 4, 2016
Actual Study Completion Date : November 4, 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Gefitinib

Arm Intervention/treatment
Experimental: Gefitinib Tablet 250mg of Hunan Kelun
During the study session, healthy subjects were orally administered a single dose of Gefitinib Tablet 250mg of Hunan Kelun under fasting conditions.
Drug: Gefitinib Tablet 250mg of Hunan Kelun
Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered after a 10-hour overnight fast.
Other Name: A031

Drug: Iressa® Tablet 250mg of AZN
Single dose of Iressa® Tablet 250mg of AZN was administered after a 10-hour overnight fast.
Other Name: Iressa®

Active Comparator: Iressa® Tablet 250mg of AZN
During the study session, healthy subjects were orally administered a single dose of Iressa® Tablet 250mg of AZN under fasting conditions.
Drug: Gefitinib Tablet 250mg of Hunan Kelun
Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered after a 10-hour overnight fast.
Other Name: A031

Drug: Iressa® Tablet 250mg of AZN
Single dose of Iressa® Tablet 250mg of AZN was administered after a 10-hour overnight fast.
Other Name: Iressa®




Primary Outcome Measures :
  1. Pharmacokinetic parameter:Cmax [ Time Frame: before drug delivery through 216 hours after dosing ]
    Peak Plasma Concentration (Cmax)

  2. Pharmacokinetic parameter:AUC [ Time Frame: before drug delivery through 216 hours after dosing ]
    Area under the plasma concentration versus time curve (AUC)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy male subjects.
  2. At least 18 years of age .
  3. Weight at least 50kg and body mass index between 19 and 26 kg/m2.
  4. Informed consent and voluntary to sign a written informed consent.
  5. Can communicate with researchers and complete the study in accordance with the provisions of the research.

Exclusion Criteria:

  1. Abnormal diagnostic findings, and clinical significances determined by researchers (physical examination,vital sign, ECG,X-ray,blood routine examination, urine routine examination,blood biochemical examination and coagulation test).
  2. Having functional gastrointestinal disease or inadequate secretion of gastric acid or is treated for a acid suppression. Which including gastro upset, dyspepsia, gastritis, gastric ulcer, duodenal ulcer, gastric secrete melanoma, etc.
  3. Taking drugs that alter the environment of the gastrointestinal,especially alter the gastrointestinal pH,within 30 days before the first dose. Such as Proton pump inhibitors:thiophene, omeprazole, lansoprazole, esomeprazole, etc . and H2 antagonist ranitidine:cimetidine, famotidine, etc .and antacids hydrogen carbonate Sodium, magnesium oxide, aluminum hydroxide, magnesium trisilicate, etc .and gastric mucosal protective agent:sucralfate,and so on.
  4. Not comply with a unified diet or has swallowing difficulties.
  5. Allergic to any ingredient or excipients of the study drug.
  6. History of gastrointestinal disorders and severe liver and kidney diseases ,which affect the absorption or metabolism of drugs so far.
  7. History of ocular surface damaging diseases (such as corneal perforation, ulcers, etc.).
  8. History of serious blood diseases.
  9. With skin, cardiovascular, liver, kidney, digestive, neurological, psychiatric, metabolic disorders, or any other disease that can interfere with the results of the trial.
  10. History of long-term excessive drinking (more than 8 cups a day, 1 cup = 250 mL) of tea, coffee or caffeinated beverages,or 48 hours before the first dose intake of any food or drink containing caffeine (such as coffee, tea, chocolate, etc.).
  11. Ingested any drinks or foods that are rich in xanthine and grapefruit or affect the drug absorption, distribution, metabolism and excretion.
  12. A positive result in breath alcohol test or previous alcohol abuse (ie, men drink more than 28 standard units a week [1 standard unit defined as containing 14 grams of alcohol, such as would be found in a standard shot of hard liquor, a 12-ounce bottle of beer, or a 5-ounce glass of wine] Or regular drinking(more than 14 standard units of alcohol per week) within 6 months before the trial.
  13. Daily intake of more than 3 cigarettes from 3 months before the study to 48 hours before the first dose or intake of tobacco or any type of tobacco product within 48 hours before the first dose.
  14. Taking drugs that interact with gefitinib (such as CYP3A4 inhibitors: itraconazole, ketoconazole, clotrimazole, Ritonavir, etc .and CYP3A4/5 inducers:rifampicin, carbamazepine, phenobarbital, phenytoin, dexamethasone, etc .and CYP2D6 inhibitors:Fluoxetine, paroxetine , etc .) within 30 days before the first dose. And use of any prescription drugs, non-prescription drugs, Chinese herbal medicine, health products within 14 days before the first dose.
  15. Volunteer in any other clinical drug study or taking any clinical trial drug within 3 months prior to this study.
  16. Blood donation or lost more than 450mL blood within 3 months prior to the study,or has a plan to donate blood or blood components within the study period or within 3 months after the end of study.
  17. Suffering from a serious illness or having undergone major surgical procedures within 1 years before the firs dose.
  18. Abnormal blood coagulation, or having a known tendency of severe bleeding.
  19. A positive result in drug test or existing drug abuse (eg, morphine, marijuana, methamphetamine, dimethylene bisoxamine amphetamines, ketamine, etc.) within 1 year prior to the trial.
  20. A positive result in hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies, a syphilis test, or an human immunodeficiency virus (HIV) test.
  21. Having fertility planning or reluctant to take appropriate contraceptive during the study or within 6 months after the study.
  22. Other unfavorable factors diagnosed by investigators.
Layout table for additonal information
Responsible Party: Hunan Kelun Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT03050164    
Other Study ID Numbers: KL031-BE-01
First Posted: February 10, 2017    Key Record Dates
Last Update Posted: February 10, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Gefitinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action